论文部分内容阅读
目的研究测定胰腺癌Patu8988细胞的18F-氟代脱氧葡萄糖(FDG)细胞结合率方法和吉西他滨化疗后对胰腺癌Patu8988细胞摄取18F-FDG的影响。方法在不同条件下测定胰腺癌Patu8988细胞的18F-FDG细胞结合率,细胞数量为5×104～1×107/瓶,18F-FDG放射性活度为1.85～29.6kBq,反应时间为20～120min,葡萄糖浓度为0～11.1mmol/L。采用四甲基偶氮唑盐(MTT)法测定加入不同剂量(0～6mmol/L)吉西他滨10μl24h后细胞抑制率。测定加入不同剂量(0～60mmol/L)吉西他滨100μl24h后18F-FDG细胞结合率。结果当每瓶1×106个细胞、加入3.7kBq18F-FDG、葡萄糖浓度为5.55mmol/L、作用100min时,细胞结合率可达到(60.60±3.05)%。加入0、5、20、40和60mmol/L吉西他滨24h后,细胞结合率分别为(58.35±2.19)%、(56.34±1.56)%、(48.92±5.91)%、(39.14±7.40)%、(29.67±4.41)%。细胞结合率随吉西他滨剂量增加而下降,两者成负相关(r=-0.928,P<0.01)。给吉西他滨24h后,MTT实验抑制率与细胞结合抑制率成正相关(r=0.856,P<0.01)。结论吉西他滨作用24h后引起胰腺癌Patu898818F-FDG细胞结合率下降,有望用18F-FDG显像早期观测吉西他滨对胰腺癌的疗效。
Objective To study the method of determining the 18F-fluorodeoxyglucose (FDG) cell binding rate in pancreatic cancer Patu8988 cells and the effect of gemcitabine on the uptake of 18F-FDG in pancreatic cancer Patu8988 cells after chemotherapy. Methods The binding rate of 18F-FDG in pancreatic cancer Patu8988 cells was determined under different conditions. The number of cells was 5 × 104 ~ 1 × 107 / flask, the activity of 18F-FDG was 1.85 ~ 29.6kBq, the reaction time was 20 ~ 120min, Glucose concentration is 0 ~ 11.1mmol / L. The cell inhibition rate was determined by MTT method after adding 10μl of gemcitabine 10μl for different dosage (0 ~ 6mmol / L) for 24 hours. The cell binding rate of 18F-FDG after adding 100μl of gemcitabine at different dosage (0 ~ 60mmol / L) for 24h was measured. Results The cell binding rate reached 60.60 ± 3.05% when 1 × 106 cells per flask, 3.7kBq18F-FDG, 5.55mmol / L glucose and 100min. The cell binding rates were (58.35 ± 2.19)%, (56.34 ± 1.56)%, (48.92 ± 5.91)% and (39.14 ± 7.40)% respectively after adding 0, 5, 20, 40 and 60 mmol / 29.67 ± 4.41)%. Cell binding rate decreased with the increase of dose of gemcitabine, the two had a negative correlation (r = -0.928, P <0.01). After gemcitabine for 24 hours, the inhibitory rate of MTT assay was positively correlated with the inhibitory rate of cell binding (r = 0.856, P <0.01). Conclusion Gemcitabine induced a decrease in the binding rate of pancreatic cancer Patu898818F-FDG cells after 24h, and it is expected that 18F-FDG imaging could be used to observe the effect of gemcitabine on pancreatic cancer early.